Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ferric Carboxymaltose Injection [Ferinject]

Phase 2

AAFT Pharmaceuticals, Ltd.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Restless Legs Syndrome (RLS)Not yet recruiting

Restless Legs Syndrome (RLS)Phase 2

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Iron Deficiency Anemia (IDA)

NCT07687784

Q4 2030

Phase 2Not yet recruiting

Restless Legs Syndrome (RLS)

NCT07822607

Clinical

Trials by Indication[1]

Restless Legs Syndrome (RLS)1 trial

Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS

Not yet recruiting·UUniversity Hospital, Montpellier·Phase 2·NCT07822607·66 enrolled

Iron Deficiency Anemia (IDA)1 trial

A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)

Not yet recruiting·AAFT Pharmaceuticals, Ltd.·Phase 3·NCT07687784·1,366 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ferric Carboxymaltose Injection [Ferinject]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ferric Carboxymaltose Injection [Ferinject]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AFT Pharmaceuticals, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAFT Pharmaceuticals, Ltd.

Related News